EW ▲ +0.7% - Edwards Lifesciences Corporation $EW - Edwards Lifesciences Comments on TAVR National Coverage Decision Edwards Lifesciences rose 0.7% following the company's comments on a national coverage decision for its TAVR (transcatheter aortic valve replacement) technology. The stock's modest gain suggests investor confidence in how the coverage ruling affects the company's core structural heart business, though the limited price movement indicates the market is digesting more details before making a larger assessment. 10-SEP-2026 05:54 PM ET